ImmunityBio Wins EU Nod for Bladder Cancer Combo Therapy, Stock Up

Key Takeaways IBRX soars 41.9% after the EC cleared Anktiva plus BCG for BCG-unresponsive NMIBC CIS in the EU.The IBRX combo therapy showed a 71% complete response rate in the phase II/III QUILT-3.032 study.IBRX to submit more data to confirm Anktiva's efficacy and safety, with EU approval subject to annual renewal.Shares of ImmunityBio, Inc. (IBRX) soared 41.9% on Wednesday after the company announced that the European Commission (EC) has granted conditional marketing authorization for Anktiva (nogapendeki ...